Genomics of Renal Cancer in Patients of African Ancestry

项目摘要 在肾细胞癌（RCC）亚型中，黑人患者的结局比白色患者差。黑色 与白色患者群体相比， 乳头状亚型环境和结构因素可能导致这种差异;然而， 有证据表明，体细胞基因组差异也有贡献。非洲患者（AFR） 祖先在大多数公开数据库中代表性不足，VHL基因突变减少， 与欧洲人（EUR）相比，观察到AFR血统的透明细胞RCC患者的染色体3 p缺失 祖先在我们增加样本量的初步数据中，我们发现NF 2突变和染色体22 q 在来自AFR血统的患者的RCC中，缺失在亚型中更常见。这些初步结果 基因组与祖先的相关性使我们假设，生存差异可能部分解释 AFR患者肿瘤中富集的分子特征。 在这个项目中，我们将采取三种平行的方法来了解分子肿瘤的差异， AFR和EUR血统的患者。在第一个目标中，我们将执行一个全面的计算分析， 更大的RCC数据集，以验证和识别这两名患者之间新的基因组肿瘤差异 人口。在第二个目标中，我们将从功能上描述“祖先特异性”基因组改变 在初步研究中发现，包括两个非整倍性事件-染色体3 p缺失和染色体 22 q缺失。最后，在第三个目标中，我们将超越面板和外显子组测序，以确定新的驱动因素。 事件，使用全基因组测序结合RNA测序对来自黑人患者的肿瘤。的 这些实验的结果将使我们对该患者肾细胞癌的特异性生物学有新的认识 人口我们的研究将揭示与祖先相关的驱动因素改变，不仅可以改善诊断， 检测AFR血统的RCC患者，但也将确定新的治疗靶点，以减少差异 在RCC中观察到。

PROJECT SUMMARY The outcomes of Black patients are worse than white patients across renal cell carcinoma (RCC) subtypes. Black patients also suffer higher disease incidence compared to the white patient population, particularly for the papillary subtype. Environmental and structural factors likely contribute to this disparity; however, there is evidence suggesting that somatic genomic differences also contribute. Although patients of African (AFR) ancestry are under-represented in most publicly available databases, decreased VHL gene mutation and chromosome 3p deletion in clear cell RCC patients of AFR ancestry was observed compared to European (EUR) ancestry. In our preliminary data with increased sample size, we found NF2 mutations and chromosome 22q deletion to be more frequent in RCCs from patients of AFR ancestry across subtypes. These preliminary findings of genomic correlations with ancestry lead us to hypothesize that the survival disparity may be partially explained by molecular features enriched in tumors from patients of AFR ancestry. In this project, we will take three parallel approaches to understanding the molecular tumor differences between patients of AFR and EUR ancestry. In the first aim, we will perform a comprehensive computational analysis of larger RCC datasets to validate and identify new genomic tumor differences between these two patient populations. In the second aim, we will functionally characterize the “ancestry-specific” genomic alterations identified in preliminary studies, including two aneuploidy events - chromosome 3p deletion and chromosome 22q deletion. Lastly, in the third aim, we will move beyond panel and exome sequencing to identify new driver events, using whole-genome sequencing coupled with RNA-sequencing on tumors from Black patients. The results from these experiments will lead to new insights about the specific biology of RCC in this patient population. Our studies will reveal ancestry-associated driver alterations that could not only improve diagnostic testing for RCC patients of AFR ancestry, but will also identify new therapeutic targets to decrease the disparities observed in RCC.